Nanocurcumin for Prostate Cancer Patients Undergoing Radiotherapy (RT)
NCT ID: NCT02724618
Last Updated: 2017-10-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
64 participants
INTERVENTIONAL
2016-03-31
2022-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Curcumin plus RT
120mg/day nanocurcumin during RT course
Curcumin
120mg/d oral nanocurcumin (3 capsules of SinaCurcumin®40 per day) 3 days before and during radiotherapy
RT
EBRT is delivered as Intensity-Modulated Radiation Therapy (IMRT) or 3D-conformal RT
Placebo plus RT
120mg/day placebo of nanocurcumin during RT course
RT
EBRT is delivered as Intensity-Modulated Radiation Therapy (IMRT) or 3D-conformal RT
Placebo
Placebo (3 placebo capsules of SinaCurcumin®40 per day), 3 days before and during radiotherapy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Curcumin
120mg/d oral nanocurcumin (3 capsules of SinaCurcumin®40 per day) 3 days before and during radiotherapy
RT
EBRT is delivered as Intensity-Modulated Radiation Therapy (IMRT) or 3D-conformal RT
Placebo
Placebo (3 placebo capsules of SinaCurcumin®40 per day), 3 days before and during radiotherapy
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Candidate for External Beam Radiotherapy
* ECOG performance status 0-2
Exclusion Criteria
* Patients with Kidney \& Liver dysfunction
* Gastrointestinal disorders such as IBD, reflux and peptic ulcers
* Any adverse reaction to curcumin
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Behnam Daheshpour Charity Organization, Tehran, Iran
UNKNOWN
Shahid Beheshti University of Medical Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Bahram Mofid
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Abolfazl Razzaghdoust
Role: STUDY_DIRECTOR
Shahid Beheshti University of Medical Sciences
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shohada-e-Tajrish Medical Center
Tehran, , Iran
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
406
Identifier Type: -
Identifier Source: org_study_id